Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Citi
UBS
Daiichi Sankyo
Merck
Farmers Insurance
Deloitte
Argus Health

Generated: May 24, 2018

DrugPatentWatch Database Preview

OFORTA Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Oforta patents expire, and when can generic versions of Oforta launch?

Oforta is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-nine patent family members in thirty-four countries.

The generic ingredient in OFORTA is fludarabine phosphate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fludarabine phosphate profile page.
Summary for OFORTA
International Patents:69
US Patents:2
Applicants:1
NDAs:1
Bulk Api Vendors: 57
Clinical Trials: 4
Patent Applications: 4,856
Formulation / Manufacturing:see details
DailyMed Link:OFORTA at DailyMed
Drug patent expirations by year for OFORTA
Synonyms for OFORTA
((2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate
[(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
{[(2R,3S,4S,5R)-5-(6-AMINO-2-FLUORO-9H-PURIN-9-YL)-3,4-DIHYDROXYOXOLAN-2-YL]METHOXY}PHOSPHONIC ACID
1X9VK9O1SC
2-F-ara-AMP
2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine
2-Fluoro-ARA AMP
2-Fluoro-ara-AMP
2-Fluoroadenine arabinoside 5'-monophosphate
2F-ara-AMP
607F679
75607-67-9
9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE-5'-DIHYD
9-beta-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate
9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-
AB0014146
AC1L1K7D
AK162583
AKOS024464516
Ambap13311-84-7
AOB4772
API0002720
AS-14202
AX8034836
BCP0726000268
BCP9000694
Beneflur
C-21000
C10H13FN5O7P
CC-28457
CCG-213521
CF0043
CHEBI:63599
CHEMBL1096882
CS-0861
D01907
DTXSID2023060
F-ara-AMP
FAMP
FaraAMP
Fluclarabine phosphate
fludara
Fludara (TN)
Fludarabine (phosphate)
Fludarabine 5'-monophosphate
Fludarabine monophosphate
fludarabine phosphate
Fludarabine Phosphate (Fludara)
Fludarabine phosphate (JAN/USP)
Fludarabine phosphate [USAN:BAN]
Fludarabine phosphate [USAN:USP:BAN]
Fludarabine phosphate;
Fludarabine Phosphate(Fludara)
Fludarabinephosphate
Fludura
fluoro-ara-AMP
FT-0630840
GIUYCYHIANZCFB-FJFJXFQQSA-N
HMS2094O11
HY-B0028
J10402
K294
KB-51878
LS-126393
MFCD00866418
MLS003915617
MLS004774150
MolPort-003-666-877
NSC 312887
NSC 328002
NSC-312887
NSC-312887|||[(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
NSC-759194
NSC759194
NU001826
NU001827
Pharmakon1600-01505705
PubChem21445
RL04879
s1229
SBI-0206893.P001
SC-13783
SCHEMBL3511
SHT-586
SMR002544683
SR-05000001945
SR-05000001945-4
SRI-5907_05
SRI-5907_07
SRI-5907-04
ST24047210
UNII-1X9VK9O1SC
W-5142
Z2235802254
ZINC3927870

US Patents and Regulatory Information for OFORTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us OFORTA fludarabine phosphate TABLET;ORAL 022273-001 Dec 18, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us OFORTA fludarabine phosphate TABLET;ORAL 022273-001 Dec 18, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Premature patent expiration for: OFORTA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Sign Up OFORTA ➤ Sign Up

Non-Orange Book US Patents for OFORTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,046,322 Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Julphar
US Army
McKesson
Cerilliant
Daiichi Sankyo
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.